Loading
A phase 2/3 trial of Remimazolam in childhood cancers, run by Acacia Pharma Ltd, active and no longer recruiting.
Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures is a phase 2/3 interventional study registered as NCT04851717 by Acacia Pharma Ltd, with 100 participants enrolled, started 2021-11-15 and due to reach its primary completion in 2027-10. Interventions recorded: Remimazolam.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/